ALLR revenueQ2 2026$0
- QoQ
- -100.0%
ALLR revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier and down 100.0% from the prior quarter. For the full fiscal 2025 it was $320.0K, compared with $0 in fiscal 2024.
Allarity Therapeutics Inc. (ALLR) financials
For fiscal 2025 (ended Dec 31, 2025), Allarity Therapeutics Inc. reported $320.0K of revenue and -$11.23M of net income.
- Revenue, FY2025
- $320.0K
- Net income, FY2025
- -$11.23M
- Net margin
- -3509.7%
- Free cash flow, FY2025
- -$14.83M
- Cash
- $16.98M
- P/S
- 47.74
- Market cap
- $15.3M
FY2024FY2025
FY2020FY2025
FY2020FY2025
ALLR revenue and earnings growth
ALLR net incomeQ2 2026-$3.40M
ALLR net income was -$3.40M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.32M a year earlier. For the full fiscal 2025 it was -$11.23M, compared with -$24.52M in fiscal 2024.
ALLR free cash flowQ2 2026-$2.56M
ALLR free cash flow was -$2.56M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.48M a year earlier. For the full fiscal 2025 it was -$14.83M, compared with -$17.65M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | $320.0K | $0 | - | - | - | - |
| Gross profit | - | - | - | -$2.27M | - | - |
| Research and development | $6.60M | $6.10M | $7.10M | $6.93M | $14.20M | $4.22M |
| Selling, general and admin | $6.32M | $11.44M | $10.03M | $9.96M | $12.36M | $4.10M |
| Operating income | -$12.61M | -$27.24M | -$17.13M | -$34.46M | -$26.56M | -$8.32M |
| Interest expense | $185.0K | $653.0K | $498.0K | $223.0K | - | $93.0K |
| Pre-tax income | -$11.23M | -$24.90M | -$11.82M | -$17.58M | - | - |
| Income tax | $0 | -$381.0K | $83.0K | -$1.52M | $133.0K | $198.0K |
| Net income | -$11.23M | -$24.52M | -$11.90M | -$16.06M | -$26.65M | -$6.62M |
| EPS, basic | -$0.78 | -$15.65 | -$6031.31 | -$61868.40 | -$83.80 | -$40.60 |
| EPS, diluted | - | - | -$205.20 | -$61868.40 | -$83.80 | - |
| Diluted shares | - | - | 99,537.4 | 340.25 | 317,949.4 | 163,239 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $14.69M | $19.53M | $166.0K | $2.03M | $19.55M | $298.0K |
| Current assets | $17.93M | $22.34M | $1.97M | $4.97M | $21.40M | $1.72M |
| Total assets | $18.26M | $22.65M | $11.86M | $14.54M | $49.63M | $33.40M |
| Current liabilities | $8.43M | $10.84M | $14.17M | $11.22M | $20.72M | $5.53M |
| Short-term debt | $0 | - | $250.0K | - | - | - |
| Long-term debt | - | - | - | $1.08M | $979.0K | - |
| Total debt | - | - | $2.69M | $1.08M | $979.0K | - |
| Total liabilities | $8.43M | $10.84M | $14.61M | $12.65M | $30.85M | $8.96M |
| Shareholders' equity | $9.83M | $11.81M | -$2.75M | -$113.0K | $18.15M | $24.44M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.82M | -$17.35M | -$12.74M | -$16.82M | -$14.89M | -$7.25M |
| Capital expenditures | $8.0K | $298.0K | $0 | $18.0K | - | $3.0K |
| Free cash flow | -$14.83M | -$17.65M | -$12.74M | -$16.84M | - | -$7.25M |
| Investing cash flow | -$8.0K | -$298.0K | $0 | $791.0K | $1.00M | -$3.0K |
| Financing cash flow | $10.65M | $36.79M | $10.99M | -$1.31M | $33.82M | $6.03M |
| Share repurchases | $3.19M | $0 | - | - | - | - |
| Stock-based compensation | $482.0K | $71.0K | -$71.0K | $1.75M | $6.37M | $616.0K |
| Depreciation and amortization | - | $9.0K | $37.0K | $60.0K | $106.0K | $46.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating margin | -3939.1% | - | - | - | - | - |
| Net margin | -3509.7% | - | - | - | - | - |
| Free cash flow margin | -4633.8% | - | - | - | - | - |
| Return on equity | -114.3% | -207.6% | - | - | -146.8% | -27.1% |
| Return on assets | -61.5% | -108.2% | -100.3% | -110.4% | -53.7% | -19.8% |
| Current ratio | 2.13 | 2.06 | 0.14 | 0.44 | 1.03 | 0.31 |
| Debt to equity | - | - | - | - | 0.05 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $25.0K | - | - | $0 | $0 | - | - | - | - | - | - |
| Research and development | $1.34M | $1.30M | $1.67M | $1.20M | $2.32M | $1.40M | $1.85M | $1.02M | $1.06M | $2.17M | $2.62M | $1.95M |
| Selling, general and admin | $1.33M | $1.42M | $1.56M | $1.31M | $1.81M | $1.63M | $5.47M | $1.59M | $2.31M | $2.07M | $2.26M | $2.48M |
| Operating income | -$2.67M | -$2.69M | -$2.92M | -$2.52M | -$4.13M | -$3.04M | -$7.32M | -$12.31M | -$3.37M | -$4.24M | -$4.88M | -$4.43M |
| Interest expense | $719.0K | $229.0K | $59.0K | $57.0K | $12.0K | $57.0K | $75.0K | $50.0K | $426.0K | $102.0K | $230.0K | $34.0K |
| Pre-tax income | - | - | -$3.37M | -$2.81M | -$2.32M | -$2.73M | -$7.45M | -$11.97M | -$1.63M | -$3.85M | -$1.64M | -$4.45M |
| Income tax | - | - | $0 | $0 | $0 | $0 | $0 | -$377.0K | $0 | -$4.0K | $83.0K | $0 |
| Net income | -$3.40M | -$2.75M | -$3.37M | -$2.81M | -$2.32M | -$2.73M | -$7.45M | -$11.59M | -$1.63M | -$3.84M | -$1.72M | -$4.45M |
| EPS, basic | -$0.21 | -$0.17 | - | -$0.19 | -$0.15 | -$0.25 | - | -$7.71 | -$3.34 | -$664.16 | - | -$1346.09 |
| EPS, diluted | - | - | - | - | - | - | - | - | -$0.11 | -$442.80 | - | -$40.60 |
| Diluted shares | - | - | - | - | - | - | - | - | 15.0M | 8,763.3 | - | 123,736.2 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $16.98M | $19.81M | $14.69M | $16.89M | $17.80M | $25.20M | $19.53M | $18.50M | $19.23M | $312.0K | $166.0K | $1.40M |
| Current assets | $31.73M | $34.50M | $17.93M | $20.47M | $20.88M | $29.42M | $22.34M | $20.37M | $21.31M | $2.29M | $1.97M | $4.39M |
| Total assets | $32.12M | $34.92M | $18.26M | $20.80M | $21.20M | $29.73M | $22.65M | $20.38M | $30.88M | $11.97M | $11.86M | $13.88M |
| Current liabilities | $28.58M | $28.00M | $8.43M | $8.79M | $9.04M | $11.06M | $10.84M | $7.41M | $10.62M | $18.01M | $14.17M | $15.74M |
| Short-term debt | $20.86M | $20.08M | $0 | - | - | - | - | - | - | - | $250.0K | - |
| Long-term debt | - | - | - | - | - | - | - | - | $1.32M | $1.32M | - | $1.17M |
| Total debt | - | - | - | - | - | - | - | - | $1.32M | $1.32M | $2.69M | $1.17M |
| Total liabilities | $28.58M | $28.00M | $8.43M | $8.79M | $9.04M | $11.06M | $10.84M | $7.41M | $11.05M | $18.44M | $14.61M | $17.25M |
| Shareholders' equity | $3.54M | $6.92M | $9.83M | $12.01M | $12.17M | $18.67M | $11.81M | $12.96M | $19.84M | -$6.47M | -$2.75M | -$3.38M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.56M | -$4.49M | -$3.24M | -$3.41M | -$5.48M | -$2.69M | -$3.21M | -$5.44M | -$7.30M | -$1.40M | -$1.67M | -$5.38M |
| Capital expenditures | $0 | $64.0K | - | - | $0 | $0 | - | - | - | - | - | - |
| Free cash flow | -$2.56M | -$4.56M | - | - | -$5.48M | -$2.69M | - | - | - | - | - | - |
| Investing cash flow | $0 | -$64.0K | - | - | $0 | $0 | - | - | - | - | - | - |
| Financing cash flow | $0 | $19.74M | -$240.0K | $2.31M | -$2.56M | $11.14M | $4.24M | $4.87M | $26.31M | $1.38M | $522.0K | $6.45M |
| Share repurchases | $0 | $262.0K | $484.0K | $141.0K | $2.56M | $0 | $0 | $0 | - | - | - | - |
| Stock-based compensation | $188.0K | $160.0K | $47.0K | $132.0K | $164.0K | $139.0K | $64.0K | $17.0K | $22.0K | -$32.0K | -$254.0K | $124.0K |
| Depreciation and amortization | - | - | - | - | $12.0K | $11.0K | $1.0K | $5.0K | $1.0K | $2.0K | $9.0K | $9.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | - | -10752.0% | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | -11000.0% | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | -18228.0% | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 1.11 | 1.23 | 2.13 | 2.33 | 2.31 | 2.66 | 2.06 | 2.75 | 2.01 | 0.13 | 0.14 | 0.28 |
| Debt to equity | - | - | - | - | - | - | - | - | 0.07 | - | - | - |
Source: XBRL data Allarity Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 5, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ALLR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ALLR | $320.0K | - | -$11.23M | -3509.7% | $15.3M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
ALLR FAQ
6 questionsWhat is ALLR revenue?
Allarity Therapeutics Inc. (ALLR) reported $320.0K of revenue for fiscal 2025 (ended Dec 31, 2025).Is ALLR profitable?
No. Allarity Therapeutics Inc. reported a net loss of $11.23M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ALLR have?
Allarity Therapeutics Inc. reported $16.98M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ALLR free cash flow?
Allarity Therapeutics Inc. generated -$14.83M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$14.82M less capital expenditures.When did ALLR last report financial results?
The latest statements here come from Allarity Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this ALLR financial data come from?
Quantisnow builds these statements from the structured XBRL data Allarity Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.